NovelStem International Corp. (NSTM) stock: key figures, P/E, revenue and dividend
Consumer Discretionary · United States
NovelStem International Corp. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Operating income | -927,922.00 USD | -238,755.00 USD |
| EBIT | -2.81 m USD | 2.42 m USD |
| Net income | -3.23 m USD | 2.38 m USD |
| Diluted EPS – continuing operations | -0.07 USD | 0.05 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NovelStem International Corp.
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
More stocks
- Professional Diversity Network, Inc. (IPDN)
- Digital Brand Media & Marketing Group, Inc. (DBMM)
- Kaival Brands Innovations Group, Inc. (KAVL)
- Marvion Inc. (MVNC)
- BNB PLUS CORP. (BNBX)
- Target Group Inc. (CBDY)
- SATIVUS TECH CORP. (SATT)
- Cyber Enviro-Tech, Inc. (CETI)
- Mitesco, Inc. (MITI)
- Trinseo PLC (TSEOQ)
- Radiant Strategies Corp (RDSC)
- AUDDIA INC. (AUUD)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.